v3.26.1
Investments in associates (Tables)
12 Months Ended
Dec. 31, 2025
Investments in associates  
Schedule of amounts recognised in the balance sheet and income statement

​

​

​

​

​

​

​

​

​

​

2025

​

2024

​

2023

​

  ​ ​ ​

$ million

  ​ ​ ​

$ million

​

$ million

Balance sheet

​

121

​

7

​

16

Income statement gain/(loss)

​

4

​

(10)

​

(30)

Reversal of impairment of interest in associate

​

109

​

–

​

–

Summary of financial information for Bioventus, adjusted for differences with Group accounting policies

​

​

​

​

​

​

​

​

​

​

2025

  ​

2024

​

2023

​

  ​ ​ ​

$ million

  ​ ​ ​

$ million

​

$ million

Summarised statement of comprehensive income

​

  ​

​

​

​

  ​

Revenue

​

410

​

420

​

377

Attributable profit / (loss) for the year

​

8

​

(34)

​

(152)

Group adjustments1

​

9

​

(2)

​

46

Total comprehensive profit / (loss)

​

17

​

(36)

​

(106)

Group share of gain / (loss) for the year at 26.60% (2024: 27.13%, 2023: 27.96%)

​

5

​

(10)

​

(30)

​

​

​

​

​

​

​

​

2025

  ​

2024

​

  ​ ​ ​

$ million

  ​ ​ ​

$ million

Summarised balance sheet

​

  ​

​

  ​

Non-current assets

​

421

​

471

Current assets

​

281

​

299

Non-current liabilities

​

(333)

​

(371)

Current liabilities

​

(162)

​

(211)

Net assets

​

207

​

188

Net equity attributable to owners

​

207

​

188

Group’s share of net assets at 26.60% (2024: 27.13%)

​

55

​

51

Group adjustments1

​

64

​

(45)

Group’s carrying amount of investment at 26.60% (2024: 27.13%)

​

119

​

6

1Group adjustments include adjustments to align with Group policy.